ARTICLE | Clinical News
Flibanserin regulatory update
May 18, 2015 7:00 AM UTC
FDA’s Bone, Reproductive and Urologic Drugs and Drug Safety and Risk Management advisory committees will meet on June 4 to discuss a resubmitted NDA from Sprout for flibanserin to treat hypoactive sex...